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1. Introduction
Cancer is a disease caused by an uncontrolled division of abnormal cells in a part of the
body, in another words, is a malignant growth or tumor resulting from such a division of
cells. Is the leading cause of death worldwide. Attributed 7.6 million deaths (approximately
13% of total) occurred worldwide in 2008. The most common types of cancer are shown in
Figure 1 [1]
• Gastric (736,000 deaths);
• Liver (695,000 deaths);
• Colorectal (608,000 deaths);
• Pancreas (227,000 deaths).
Figure 1. Cancer deaths in 2008
© 2013 Valencia and Rodriguez-Wulff; licensee InTech. This is an open access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cancers that cause more deaths per year are lung, stomach, liver, colon and breast.
In this problem, are involving genetic factors and lifestyle of the population, approximately
30% of cancer deaths are due to five behavioral risk factors and diet: high body mass index,
reduced intake of fruits and vegetables, sedentary lifestyle, smoking and alcohol use.
More than 50% of cancer could be prevented if people implemented what is already known
about cancer prevention, according to researchers at the Union for International Cancer
Control (UICC) World Cancer Congress 2012 [2].
In this chapter, we summarize the relationship of some gastrointestinal cancer and factors
that can be change in our population to decrease and prevent them in the future.
2. Helicobacter pylori and gastric cancer
Gastric cancer is the second leading cause of cancer death in the world [3,4,5]. A number of
environmental factors such as Helicobacter pylori status, smoking, alcohol, decrease vitamin
C intake, nitrosamines and nitrates, and salt intake are related to gastric cancer develop‐
ment. Also the presence of a family history of gastric cancer is significantly associated with
increased risk of developing the disease [6] Figure 2. Gastric carcinogenesis is a multifactori‐
al process, involving complex interactions between host and environmental factors [7]. It is
known that gastric cancer involves the interaction of three major factors: the agent (in the
great part of the cases, H. pylori) and its pathogenicity, the characteristics of the host, and
the external environment [8].
Among these factors, have been associated with the development of gastric cancer, prema‐
lignant conditions within which include chronic atrophic gastritis, intestinal metaplasia,
Helicobacter pylori infection and gastric adenoma [3,4,5,8]. Chronic inflammation plays an
important role in the development of gastric cancer. Inflammation-induced injury may com‐
promise tissue integrity and drive the multistage process of carcinogenesis by altering tar‐
gets and pathways crucial to normal tissue homeostasis [7].
Helicobacter pylori (H. pylori), is a spiral, Gram-negative microaerophilic bacterial patho‐
gen that is distributed worldwide and is in particular found in developing countries, infect‐
ing the stomach of about 50 % of the world’s population [9]. H. pylori infection is closely
related to the development of gastric cancer [10]. In 1994 the results of epidemiological stud‐
ies carried, the World Health Organization’s International Agency for Research on Cancer to
concluded that H. pylori has a causal link with gastric carcinogenesis and was defined as a
type I carcinogen, a definite human carcinogen [10,8]. The evidence in the population of
whole world shows that H. pylori infection, has been known to induce chronic gastric in‐
flammation that leads to atrophy, metaplasia, dysplasia, and gastric cancer [3,7]. All patients
with H. pylori infection have histological gastritis, which corresponds to classical chronic
gastritis and is characterized by the infiltration of neutrophils and other inflammatory cells.
However, most patients are asymptomatic for life, while only some will come to develop a
digestive disease [8]. The transmission route of H. pylori infection has been the topic of sev‐
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eral studies. Most infections are probably acquired in childhood, mainly via oral-oral or fe‐
cal-oral routes; H. pylori has been found in saliva, dental plaques and feces, which shows
that oral and fecal cavities are probably involved in H. pylori transmission, however, the ex‐
act mode of transmission is still unknown [11].
Gastric cancer can develop both in the proximal and the distal region. Dietary factors and H.
pylori infection are major risk factors for the development of distal tumors; the major risk
factors for proximal cancers are gastroesophageal reflux disease and obesity [5].
The gastric intestinal metaplasia is recognized as a premalignant condition that may be the
result of adaptive response to environmental stimuli such as infection by H. pylori, smoking
and high concentrations of salt intake. Patients with intestinal metaplasia are up to 10 times
greater risk of developing gastric cancer, which may be higher in certain geographical areas
and in patients infected with H. pylori [12]. Figure 3.
Despite advances in diagnosis, the disease is usually detected after invasion of the muscular
propia, because most patients experience vague and nonspecific symptoms in the early
stages and the classic triad of anemia, weight loss, and refusal of meat-based foods is seen
only in advanced stages. Furthermore, surgery and chemotherapy have limited value in ad‐
vanced disease and there is a paucity of molecular markers for targeted therapy. Since can‐
Figure 2. Associated factors in Gastric Cancer
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cer of the stomach has a very poor prognosis and the 5-year survival rate is only around 20
per cent, a new look at the results of epidemiological and experimental studies is important
to establish strategies for primary prevention [5]. As treatment of gastric cancer at the symp‐
tomatic stage represents a significant medical burden, clinicians have been encouraged to fo‐
cus on designing preventive strategies instead of multimodal therapies [13].
Figure 3. Gastric carcinogenesis: Histologyc changes from normal gastric mucosa to neoplasia.
As a primary prevention, some behavior modifications have been suggested, including re‐
duction of salt intake with the diet, increase of vitamin C consumption, abolition of smoking
and H. pylori eradication wich is recommended as it is able to reduce gastric cancer inci‐
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dence up to 35% [14]. If infection with H. pylori is identified, eradication should be consid‐
ered the same because it is considered a class I carcinogen [12]. After eradicating H. pylori,
precancerous lesions may regress. Testing and treating for the H pylori infection earlier rath‐
er than later in life is suggested to be the more beneficial approach [7]. The eradication of H.
pylori prophylactically pylori remains controversial in humans, has not shown a significant
reduction in the risk of gastric cancer after eradication of H pylori [10], but in a recent popu‐
lation-based study, early H pylori eradication was found to be associated with decreased
risk of gastric cancer [7]. There are some studies indicating that the eradication of the micro‐
organisms in the system could reduce the incidence of gastric cancer in patients without pre‐
cancerous lesions or, when lesions are presents, that the eradication may or may not reduce
this incidence. Also, when the eradication is done after endoscopic mucosal resection in pa‐
tients with early gastric adenocarcinoma, it could decrease the recurrence of metachronous
gastric cancer in some patients [8].
3. Hepatitis virus and liver cancer
The hepatocellular carcinoma (HCC), is the most frequent form of primary liver cancer [15],
it accounts for up to 90% [16], and is one of the most common malignancies in the world
[17], is the third most common cause of cancer-related death worldwide [18,19], results in
between 250.000 and one million deaths globally per annum, the increasing incidence rates
are in many parts of the world, including the United States and Central Europe. The Inci‐
dence of HCC in the United States is expected to continue to rise as a consequence of high
hepatitis C infection rates between 1960 and 1990 and the average 20 to 30 year lag time be‐
tween virus acquisition and the development of cirrhosis and carcinoma.
Cancers caused by viral infections such as infections of hepatitis B virus (HBV), hepatitis C
virus (HCV) and human papillomavirus (HPV), are responsible for up to 20% of cancer
deaths in middle-income countries low and medium [1]. The major risk factors for the devel‐
opment of HCC include liver cirrhosis of any etiology [16]. Almost 80 percent of cases are
due to underlying chronic hepatitis B and C virus infection [19]. Occur with particular fre‐
quency in patients with cirrhosis caused by hepatitis virus. HCC can develop in patients
with chronic HBV, even in the absence of cirrhosis. However, 70 to 90 percent of patients
with HBV who develop HCC will have cirrhosis [18]. The strong association between liver
cancer and cirrhosis has been recognized in patients with HCV [17]. Chronic infection of
HBV and hepatitis C virus are well-documented major etiologic factors for HCC [20,21].
The majority of HCC occur in patients with chronic liver disease or cirrhosis. Thus, older pa‐
tients with longstanding liver disease are more likely to develop HCC, it develops common‐
ly, but not exclusively, in a setting of chronic liver cell injury, inflammation which leads to,
hepatocyte regeneration, liver matrix remodeling, fibrosis, and ultimately, cirrhosis. The ma‐
jor etiologies of liver cirrhosis are diverse and include chronic HBV and HCV, alcohol con‐
sumption, steatosis, diabetes, certain medications or toxic exposures, including dietary
aflatoxins and genetic metabolic diseases [22,23]. In addition to cirrhosis, a number of other
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factors have been associated with the risk of developing HCC among patients with chronic
HBV, including the viral load, the presence of hepatitis B e antigen (HBeAg), and the pres‐
ence of hepatitis B surface antigen (HBsAg). The risk of HCC is much greater in patients
with high serum levels of HBV DNA compared with those who have low levels (<10,000
copies/mL). Figure 4.
HCC: Hepatocellular Carcinoma. HBV: Virus Hepatitis B. HBs Ag: Hepatitis B surface antigen. HBe Ag: Hepatitis B e anti‐
gen
Figure 4. Factors associated with the risk of develop HCC in patients with chronic HBV
The mechanisms by which these varied etiologies lead to cirrhosis and HCC are not yet fully
understood [21,22,23]. A common pathway from these varied etiologies to HCC may in‐
volve chronic inflammation, which is increasingly recognized as a procarcinogenic condi‐
tion [21,22]. Both viruses have been classified as human carcinogens by the International
Agency for Research on Cancer [20]. Malignant transformation that is induced by chronic
HBV infection is a multistage pathogenic process and involves multiple risk predictors [20].
Other many factors determining the risk of developing an HCC are host dependent, some
are genetic and not modifiable, other are linked to lifestyle and can be influenced [15]; age,
gender, family history of HCC, alcohol consumption habits, serostatus of hepatitis B e anti‐
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gen, HBV genotype and mutant types, as well as serum quantitative levels of ALT and HBV
DNA are important long-term risk predictors of HCC [20]. Figure 5.
HCC: Hepatocellular Carcinoma.
Figure 5. Host dependant factors that determining risk of HCC
A variety of important risk factors for the development of HCC have been identified. These
include viral infections, environmental toxins, comorbid conditions, inherited errors of me‐
tabolism, and autoimmune disorders [18]. At one major referral center in the United States,
the most commonly seen risk factors for HCC were HCV infection, alcohol use, and nonal‐
coholic fatty liver disease. In a 5-year cumulative incidence, hepatocellular carcinoma in pa‐
tients with HCV cirrhosis is about 15%, the risk is increased 2-6 fold in the presence of other
risk factors such as alcohol, obesity, diabetes mellitus and HBV [24]. HBeAg positivity,
which indicates active viral replication, is also associated with the development of HCC. The
risk of HCC is also elevated in patients who are HBsAg positive but HBeAg negative (inac‐
tive carriers) compared with the general population.
Because of the association of HBV with HCC, screening for HCC is recommended for many
patients with hepatitis B. Currently, it is recommended that patients with high HBV DNA
levels and signs of active inflammation (elevated ALT) for several years undergo surveil‐
lance for HCC.
Coinfection with HCV has also been associated with an increased risk of HCC. Some studies
suggest that patients with dual HBV and HCV infection may have a higher rate of HCC
compared with patients infected by either virus alone, particularly those who are anti-HCV
and HBeAg positive. Coinfection with hepatitis D virus (HDV) also appears to increase the
risk of HCC among patients with HBV. Hepatitis C accounts for at least one-third of the cas‐
es of HCC in the United States. An important clinical observation is that HCC in patients
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with HCV occurs almost exclusively in patients with advanced stages of hepatic fibrosis or
cirrhosis.
Symptoms attributable to HCC are usually absent, when symptomatic, is often associated
with nonspecific complaints, including right upper abdominal or epigastric pain, early sati‐
ety, weight loss, and malaise. Rather, patients typically manifest symptoms related to under‐
lying cirrhosis, a condition present in 80%–90% of patients with HCC. Consequently, the
majority of patients are diagnosed with advanced disease, often precluding potentially cura‐
tive therapies. HCC is associated with a number of paraneoplastic syndromes resulting in
hypoglycemia, erythrocytosis, hypercholesterolemia, hypercalcemia, severe watery diar‐
rhea, and cutaneous manifestations. Extrahepatic spread at presentation is relatively uncom‐
mon, ranging between 10% and 30% [18].
Eradicating the main viruses associated with cancer worldwide by implementing wide‐
spread infant and childhood immunization programs targeting 3 viruses — human papillo‐
mavirus and hepatitis B and C — could lead to a 100% reduction in viral-related cancer
incidence in 20 to 40 years [2].
4. Colonoscopy and colon cancer
The colonoscopy consists in visualizing the entire large bowel mucosa and the terminal
ileum, is widely used for diagnosis and treatment of diseases of the colon; performed prop‐
erly, is safe, accurate and well tolerated by most patients [25]. Is used for primary colorectal
cancer screening, monitoring of patients with colon cancer and for diagnosis in patients with
lower gastrointestinal tract symptoms, also used to evaluate patients with screening tests for
colorectal cancer such as occult blood positive stool, sigmoidoscopy, fecal DNA, or images
studies [26,27,28], having shown in ramdom studies that has been effective in reducing
deaths from colorectal cancer [28,29,30].
Colorectal cancer is a leading cause of cancer worldwide [29,31,32,33] increased in both sex‐
es with an increase in incidence and mortality, which is why we have emphasized the need
to improve prevention and control in order to modify the course of the disease and improve
prognosis [29,31,34]. The rate of colorectal cancer mortality has declined substantially in part
by the increase in the performance of studies including screening colonoscopy, which aims
to reduce mortality based on a reduction in the incidence of advanced disease [34,35].
There is evidence that most colon cancers develop from adenomatous polyps (adenoma-car‐
cinoma sequence) [36,37] and takes about 10 years when a polyp of 1 cm from becoming in‐
vasive colorectal cancer [38], the risk is higher in advanced adenomas, greater than or equal
to 1 cm and / or villous component and / or high grade dysplasia [37]. Being a long term
process which involves multiple steps, the disease is preventable, on the other hand, if the
disease is detected in a first step, the curative is possible [26].
Many colorectal cancer studies focus on symptomatic populations, however, the majority of
colorectal adenomas are asymptomatic and are detected by chance during colonoscopy [39].
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This finding that adenomatous polyps are precursors to cancer and these are usually asymp‐
tomatic, has gained strength in the screening asymptomatic individuals for early cancer de‐
tection and prevention [38].
Colonoscopy is considered the preferred tool for colorectal cancer screening
[25,29,31,32,33,38,40,41] because it allows us both to make detection and sampling of the le‐
sions and to detect and remove polypoid lesions [25,26,34,35,38,42]. Colonoscopy with re‐
moval of adenomas is a useful tool to reduce the incidence and mortality of colorectal
cancer, and is recommended as the first choice for screening in patients with intermediate
risk of colorectal cancer [36,37,43,44,45].
In individuals with average risk, the U.S. Multi-Society Task Force on Colorectal Cancer and
the American Cancer Society recommend screening should begin at age 50 regardless of sex
and race [38,46], however, the American College of Gastroenterology suggests to consider
these two factors and to be started earlier in blacks because they have a higher incidence and
age of onset of colorectal cancer earlier [46]. Other authors suggest could benefit from color‐
ectal cancer screening people with abdominal obesity or metabolic syndrome from 45 years
of age reported having these risk factors are independent [45]. In patients at high familial
risk, screening is different.
The ASGE publish this guideline for colorectal cancer screening and surveillance [38]:
1. Individuals at Risk for FAP Flexible sigmoidoscopy screening should undergo yearly
starting at age 10 to 12 years. The Development of multiple, diffuse adenomas in the co‐
lon is an indication for colectomy Total.
2. Individuals at Risk for HNPCC should undergo colonoscopy every 1 to 2 years starting
at age 20 to 25 years or 10 years younger than the age of the earliest diagnosis of cancer
in the family, whichever is earlier.
3. Individuals with a family history of 1 or more first degree relatives with sporadic CRC
regardless of age, should have a colonoscopy beginning at age 40 years or 10 years
younger than the affected relative, whichever is earlier. If the index has regular colono‐
scopy results, repeat colonoscopy should be performed on the basis of the relative age
of the affected.
4. Individuals with a first-degree relative age 60 years with adenomatous polyps should
undergo colonoscopy at age 40 years or 10 years younger than the affected relative,
whichever is earlier. If the index examination is normal, recommend repeat colonosco‐
py every 5 years.
5. In patients with a first-degree relative more than 60 years old at diagnosis of adenoma‐
tous polyps, the timing of screening colonoscopy should be individualized. The timing
interval follow-up examinations between should be the same as for average-risk pa‐
tients.
6. In individuals with UC and Crohn's extensive colitis. Surveillance colonoscopy with
multiple biopsy specimens should be performed every 1 to 2 years after beginning 8 to
10 years of disease.
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7. A complete colonoscopy should be performed in all patients diagnosed with CRC to
rule out synchronous or adenomatous lesions cancers. If a complete examination can
not be performed at the time of CRC diagnosis, a colonoscopy should be performed
within 6 months after surgical resection.
8. Surveillance colonoscopy after surgical resection of CRC should be performed 1 year af‐
ter surgery and, if results are normal, every 3 to 5 years thereafter.
Adenomatous polyps are the most frequent neoplasm found during colorectal screening
and removal of these lesions have been shown to reduce the risk for future colorectal cancer
or advanced adenomas (gastrointestinal). One of the parameters critical to the viability and
profitability of colonoscopy for colorectal cancer screening is the time interval for surveil‐
lance colonoscopy after resection of an adenoma, surveillance intervals are based primarily
on the recurrence of adenoma and not in the incidence of colorectal cancer [43]. In 2006, the
U.S. Multi-Society Task Force on Colorectal Cancer joint the American Cancer Society to
Provide a broader consensus and thereby increase the use of the recomendations by endo‐
scopists, publishing guidelines for colonoscopy surveillance These after polypectomy:
1. Patients with small rectal polyps should be considered to have normal colonoscopies
and therefore, the interval for subsequent colonoscopy should be 10 years. An exception
is patients with hyperplastic polyposis syndrome, they are at an increased risk of color‐
ectal adenomas and cancer and need to be identified for more intensive monitoring.
2. Patients with only 1 or 2 small tubular adenomas (less than 1 cm) with only low-grade
dysplasia should have their next colonoscopy control in 5 to 10 years, the precise time
within this range should be based on other clinical factors such as a result of previous
colonoscopy, family history and patient preference and physician's discretion.
3. Patients with 3 or more adenomas, adenomas larger than 1 cm or villous features or ad‐
enoma with high grade dysplasia should have their next colonoscopy in control 3 years
after complete resection of the adenoma. If the colonoscopy is normal or shows up in 1
or 2 small tubular adenomas or low-grade dysplasia, the interval for further study
should be 5 years.
4. Patients who have 10 or more adenomas in an examination, should be reevaluated in a
shorter period as 3 years, interval established by clinical judgment, it being necessary to
consider an underlying familial syndrome.
5. Patients with sessile adenomas that are removed by picemeal monitoring should be
considered for short intervals between 2-6 months to verify complete removal, which,
once established, subsequent surveillance should be individualized based on the judg‐
ment of the endoscopist, the integrity of elimination by both endoscopy and biopsy
evaluations.
6. More intensive monitoring is indicated when the family history may indicate HNPCC.
Subsequent studies suggest that it may be considered to extend surveillance intervals even
in people 5 years after detection and elimination of high-risk polyps [43].
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It has been reported that colonoscopy could prevent approximately 85% of cases of distal
colorectal cancer while the risk reduction for proximal colon is significantly lower ranging
from 0-55% [42], but colonoscopy is not perfect have been diagnosed with cancer between
the intervals of follow-up examinations, reporting an incidence rate ranging from 1.7 to 2.4
cancers per 1,000 persons / year of observation [44]. The effectiveness of colonoscopy in re‐
ducing colon cancer incidence depends on adequate visualization of the mucosa, diligence
in examining the mucosa and patient acceptance of the procedure [25]. That is why for the
reporting of colonoscopies are suggested previously structured reports that include quality
indicators such as colonoscopies specific point as far as progress, quality of bowel prepara‐
tion, cecal intubation, polyp detection [27], since it has been shown that the quality of colo‐
noscopy is also important in screening, low quality colonoscopies reduce the effectiveness
especially in the proximal colon [29]. It has been reported that conventional colonoscopy
some lesions may be missed even with adequate colonic preparation, this may be partly be‐
cause flat lesions which makes them difficult to recognize or be injuries that are located be‐
hind the colonic haustral; it is proposes that autofluorescence imaging are better for the
detection of colorectal neoplasia than conventional colonoscopy [33]. With the increase of
colonoscopy in the general population over 50 years, has contributed to the decreased inci‐
dence of colorectal cancer observed since the mid-year 1980 [40].
Should bear in mind the risk cost-benefit of screening colonoscopy for colorectal cancer in
elderly patients, remains controversial at this stage because the net benefit of screening re‐
duces the risk of mortality from other diseases, reporting especially in octogenarians, a in‐
creased risk of complications during and after colonoscopy [32], the benefits of screening are
significantly limited due to their short life expectancy [47].
A recent study showed that after a median follow-up of 11.9 years, there was a 21% relative
risk reduction in the incidence of colorectal cancer and a 26% reduction in mortality in
adults screened with flexible sigmoidoscopy, with a repeat screening at 3 or 5 years, com‐
pared with those treated with the usual care [2].
5. Obesity and pancreatic cancer
Pancreatic cancer is the eighth leading cause of cancer-related death [48], is one of the most
lethal malignant diseases due to the high rate of advanced stage disease at diagnosis, and
the lack of any affective medical therapy [49]. Currently, there are no methods of screening
established for early detection; thus, at present, primary prevention by altering modifiable
risk factors will probably be the most effective way of reducing the burden pancreatic cancer
[50]. The etiology of pancreatic cancer is complex and poorly understood, therefore the in‐
dentification of risk factors, specially those which are modifiable through medication or be‐
havioral change, is important for the development and progression preventing of pancreatic
cancer. The risk factors for pancreatic cancer include family history, smoking, obesity, diabe‐
tes mellitus and chronic pancreatitis [49,51,52,53] Figure 6.
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Figure 6. Risk factors for pancreatic cancer
Obesity is defined as abnormal or excessive accumulation of fat that can be harmful to
health [48]. A World Health Organization (WHO) report demonstrates that more than 400
million people are obese in the world, with a predicted increase to 700 million by 2015 [52].
Since 1990, the prevalence of obesity has doubled in the United States [12]. Statistics from
2007 to 2008 indicate that 33.8% of american adults are obese [51]. According to WHO/Food
and Agriculture Organization (FAO), obesity and overweight conditions can be diagnosed
by measuring the body mass index (BMI) of the individual [52]. The BMI is the ratio of cal‐
culated with weight in kilograms divided by the square of height in meters kg/m2. The cur‐
rent standard categories of BMI are as follows: underweight <18.5, normal weight 18.5-24.9,
overweight 25.0-29.9, obese 30.0-34.9, and severely obese > or = 35.0 [52,54,55].
Many studies based on large population have shown that obesity and insulin resistance are
independent risk factors may types of cancer [50,52,55,56], reporting that the strength of the
association varies with the organ and histologic type; this evidence supports the notion that
controlling obesity can be an important tool for a number of preventing cancers among the
populations of modern societies [57].
A number of recent studies indicate that obesity may be an important risk factor for pancre‐
atic diseases including pancreatitis and pancreatic cancer and is associated with a lower age
of onset [54,58]. Between the positive association with BMI and high risk of pancreatic can‐
cer has been in at least observed 19 of 29 prospective studies and three meta-analyzes. The
magnitude of the association varied from 10 to 45% increased risk for every 5 kg/m2 in‐
crease in BMI. It has been reported that people with a BMI greater than 40 kg/m2 in both
sexes have higher cancer mortality rate when compared with normal weight [59], associated
with a 50-60% death rate from cancer increased of pancreas [49]. Among the many possible
mechanisms involved, hyperinsulinemia, diet and nutritional factors, and other hormone
abnormalities have been suggested as causal factors [49]. There are sparse data on the asso‐
ciation whether between BMI and pancreatic cancer risk is modified by age, sex, smoking,
physical activity and history of diabetes [51,60]. Study showed that increased risk of pancre‐
atic cancer was more strongly associated with obesity at younger adulthood (30-40years)
than was weight gain at older age (older than 40years) [51].
In the obese patient, becomes important both visceral fat and ectopic fat, as well as waist cir‐
cumference and the waist-to-hip ratio in relation to pancreatic cancer risk [50]. It has been
described that may centralized increased fat distribution pancreatic cancer risk, especially in
women [53]. In these patients and have fat deposits in hepatocytes do in pancreatic cells, re‐
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sulting in an entity called pancreatic steatosis, it has been hypothesized that pancreatic stea‐
tosis could promote the development of chronic pancreatitis and pancreatic cancer [61].
Obesity has also been associated with major metabolic abnormalities including insulin re‐
sistance and diabetes, and therefore may be associated with the risk of pancreatic cancer.
It  has  also  demonstrated strong association between pancreatic  cancer  and two medical
conditions  chronic  pancreatitis  and  diabetes  mellitus.  Since  these  conditions  are  often
present many years before the diagnosis of cancer, they should be considered etiological‐
ly relevant [58].
Epidemiological studies have demonstrated that diabetes is a risk factor for multiple forms
of malignancy including the pancreatic cancer. Previous studies have implicated long-term
diabetes as a modifiable risk factor for pancreatic cancer [51]. Roughly half of all the patients
with pancreatic cancer are found to have diabetes at the time of diagnosis, and roughly half
of the diabetic patients present which is at the time of pancreatic cancer diagnosis is of new
onset having developed over the preceding 2-3 years the diagnosis of pancreatic cancer [49].
There has been a long debate about whether diabetes mellitus is a risk factor for, or a conse‐
quence of cancer, pancreatic cancer, but there are findings that suggest that diabetic individ‐
uals with a history of 5 or more years and have a 2-fold increase risk of pancreatic cancer
compared with those with no history of diabetes or with less than 5 years [58], reporting that
the long-standing diabetes increases the risk of pancreatic cancer [54]. The association be‐
tween pancreatic cancer and diabetes has been investigated extensively, but the causal rela‐
tionships have yet to be fully elucidated [49].
The association between type 2 diabetes and pancreatic cancer risk can be the result of high
concentrations of glucose in the after load and gradual alterations glucose tolerance for
years. It supports the hypothesis that glucose tolerance and diabetes play a role in carcino‐
genesis of pancreatic cancer.
Obesity has been associated with a negative prognostic factor, higher BMI is associated with
decreased survival and increased mortality in pancreatic cancer [54,62,63]. Furthermore, in
pancreatic cancer, increased BMI has been reported to be an adverse prognostic factor for
survival after surgery in two surgical series [63].
A majority of prospective epidemiological studies have found that a high body mass index
and/or a lack of physical activity are associated with an increased risk of pancreatic cancer
incidence or mortality, independently of prior history of diabetes [53]. Physical activity and
reduced caloric intake have to been shown to reduce the risk of pancreatic cancer especially
in those who are overweight [49,54]. The successful treatment of obesity and diabetes has
been shown to reduce the risk of pancreatic cancer, but the treatment with insulin, insulin
analogs, and insulin secretagogues maintains or increases the risk. Metformin as well as
livestyle alterations has been shown to reduce the risk of pancreatic cancer [49].
It is estimated that being overweight or obese causes approximately 20% of cancer today. If
people could maintain a healthy body mass index (BMI), the incidence of cancer could be
reduced by approximately 50% in 2 to 20 years [2].
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6. Conclusion
Having the knowledge of the cancer associated factors, interventions could be implemented
to prevent and treat it, in order to reduce and control the disease. We should apply science-
based strategies for the prevention of disease as well as early detection and treatment of
these patients.
A percentage of all cancer deaths could be prevented by modifying or avoiding key risk fac‐
tors, such as: smoke, overweight or obese, unhealthy diets with a low consumption of fruit
and vegetables, physical inactivity, consumption of alcoholic beverages, HPV infection and
HBV, air pollution in cities.
It is critical the knowledge of the risk factors to apply prevention strategies in the future to
modify the morbidity of this disease.
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